Eltoprazine dihydrochloride
Code | Size | Price |
---|
TAR-T7746-5mg | 5mg | £109.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T7746-1mL | 1 mL * 10 mM (in DMSO) | £121.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T7746-10mg | 10mg | £128.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T7746-25mg | 25mg | £173.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T7746-50mg | 50mg | £224.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T7746-100mg | 100mg | £302.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Eltoprazine dihydrochloride is a drug that had previously been developed for aggression, has recently been investigated for L-DOPA-induced dyskinesia in animal models of Parkinson?s disease (PD) and in dyskinetic PD patients.
CAS:
143485-51-2
Formula:
C12H18Cl2N2O2
Molecular Weight:
293.19
Purity:
0.9994
SMILES:
Cl.Cl.C1CN(CCN1)c1cccc2OCCOc12
References
Keywood, Charlotte, Widner, et al. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study[J]. Brain: A journal of neurology, 2015.
Gravius A , Dekundy A , Vanaga A , et al. Further pharmacological characterization of eltoprazine: Focus on its anxiolytic, anorexic, and adverse-effect potential[J]. Acta neurobiologiae experimentalis, 2017, 77(1):77-85.